ID

33558

Description

Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02135757

Lien

https://clinicaltrials.gov/show/NCT02135757

Mots-clés

  1. 13/12/2018 13/12/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

13 décembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Colorectal Cancer Metastatic NCT02135757

Eligibility Colorectal Cancer Metastatic NCT02135757

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with a histologically confirmed diagnosis of mcrc.
Description

Secondary malignant neoplasm of large intestine

Type de données

boolean

Alias
UMLS CUI [1]
C0346973
immunohistochemical evidence of egfr expression.
Description

Epidermal Growth Factor Receptor Expression Immunohistochemistry

Type de données

boolean

Alias
UMLS CUI [1,1]
C0034802
UMLS CUI [1,2]
C0597360
UMLS CUI [1,3]
C0021044
ecog performance status of 0, 1 or 2.
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
patients refractory to fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens
Description

Chemotherapy refractory | fluoropyrimidine | oxaliplatin | irinotecan

Type de données

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0205269
UMLS CUI [2]
C0596581
UMLS CUI [3]
C0069717
UMLS CUI [4]
C0123931
patients with a wt kras scheduled to receive panitumumab as a single agent for the third-line treatment of mcrc or patients with a mt kras scheduled to receive soc for third-line treatment of mcrc.
Description

Patients KRAS wt Allele | panitumumab | Third line treatment Secondary malignant neoplasm of large intestine | Patients KRAS gene Mutated | Standard of Care Third line treatment Secondary malignant neoplasm of large intestine

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1705982
UMLS CUI [2]
C0879427
UMLS CUI [3,1]
C2986605
UMLS CUI [3,2]
C0346973
UMLS CUI [4,1]
C0030705
UMLS CUI [4,2]
C1537502
UMLS CUI [4,3]
C1705285
UMLS CUI [5,1]
C2936643
UMLS CUI [5,2]
C2986605
UMLS CUI [5,3]
C0346973
signed and dated irb-approved informed consent document.
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
ability to read and understand english or french.
Description

Able to read English Language | Able to read French language | Comprehension English Language | Comprehension French language

Type de données

boolean

Alias
UMLS CUI [1,1]
C0586740
UMLS CUI [1,2]
C0376245
UMLS CUI [2,1]
C0586740
UMLS CUI [2,2]
C0376246
UMLS CUI [3,1]
C0233733
UMLS CUI [3,2]
C0376245
UMLS CUI [4,1]
C0233733
UMLS CUI [4,2]
C0376246
18 years of age or older.
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
acquired immunodeficiency syndrome (aids-related illnesses) or known hiv disease.
Description

Acquired Immunodeficiency Syndrome | Illness AIDS Related

Type de données

boolean

Alias
UMLS CUI [1]
C0001175
UMLS CUI [2,1]
C0221423
UMLS CUI [2,2]
C0001175
UMLS CUI [2,3]
C0439849

Similar models

Eligibility Colorectal Cancer Metastatic NCT02135757

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Secondary malignant neoplasm of large intestine
Item
patients with a histologically confirmed diagnosis of mcrc.
boolean
C0346973 (UMLS CUI [1])
Epidermal Growth Factor Receptor Expression Immunohistochemistry
Item
immunohistochemical evidence of egfr expression.
boolean
C0034802 (UMLS CUI [1,1])
C0597360 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
ECOG performance status
Item
ecog performance status of 0, 1 or 2.
boolean
C1520224 (UMLS CUI [1])
Chemotherapy refractory | fluoropyrimidine | oxaliplatin | irinotecan
Item
patients refractory to fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens
boolean
C0392920 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0596581 (UMLS CUI [2])
C0069717 (UMLS CUI [3])
C0123931 (UMLS CUI [4])
Patients KRAS wt Allele | panitumumab | Third line treatment Secondary malignant neoplasm of large intestine | Patients KRAS gene Mutated | Standard of Care Third line treatment Secondary malignant neoplasm of large intestine
Item
patients with a wt kras scheduled to receive panitumumab as a single agent for the third-line treatment of mcrc or patients with a mt kras scheduled to receive soc for third-line treatment of mcrc.
boolean
C0030705 (UMLS CUI [1,1])
C1705982 (UMLS CUI [1,2])
C0879427 (UMLS CUI [2])
C2986605 (UMLS CUI [3,1])
C0346973 (UMLS CUI [3,2])
C0030705 (UMLS CUI [4,1])
C1537502 (UMLS CUI [4,2])
C1705285 (UMLS CUI [4,3])
C2936643 (UMLS CUI [5,1])
C2986605 (UMLS CUI [5,2])
C0346973 (UMLS CUI [5,3])
Informed Consent
Item
signed and dated irb-approved informed consent document.
boolean
C0021430 (UMLS CUI [1])
Able to read English Language | Able to read French language | Comprehension English Language | Comprehension French language
Item
ability to read and understand english or french.
boolean
C0586740 (UMLS CUI [1,1])
C0376245 (UMLS CUI [1,2])
C0586740 (UMLS CUI [2,1])
C0376246 (UMLS CUI [2,2])
C0233733 (UMLS CUI [3,1])
C0376245 (UMLS CUI [3,2])
C0233733 (UMLS CUI [4,1])
C0376246 (UMLS CUI [4,2])
Age
Item
18 years of age or older.
boolean
C0001779 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Acquired Immunodeficiency Syndrome | Illness AIDS Related
Item
acquired immunodeficiency syndrome (aids-related illnesses) or known hiv disease.
boolean
C0001175 (UMLS CUI [1])
C0221423 (UMLS CUI [2,1])
C0001175 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial